Vikram R. Juneja

5.1k total citations · 2 hit papers
19 papers, 2.6k citations indexed

About

Vikram R. Juneja is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Vikram R. Juneja has authored 19 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 10 papers in Immunology and 5 papers in Molecular Biology. Recurrent topics in Vikram R. Juneja's work include CAR-T cell therapy research (9 papers), Cancer Immunotherapy and Biomarkers (9 papers) and Immune Cell Function and Interaction (6 papers). Vikram R. Juneja is often cited by papers focused on CAR-T cell therapy research (9 papers), Cancer Immunotherapy and Biomarkers (9 papers) and Immune Cell Function and Interaction (6 papers). Vikram R. Juneja collaborates with scholars based in United States, United Kingdom and Germany. Vikram R. Juneja's co-authors include Arlene H. Sharpe, W. Nicholas Haining, Martin W. LaFleur, Robert T. Manguso, Natalie B. Collins, Gordon J. Freeman, Kathleen A. McGuire, David E. Fisher, Jennifer A. Lo and Peter T. Sage and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and The Journal of Experimental Medicine.

In The Last Decade

Vikram R. Juneja

19 papers receiving 2.6k citations

Hit Papers

In vivo CRISPR screening identifies Ptpn2 as a cancer imm... 2017 2026 2020 2023 2017 2017 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target
    2017 774 citations Robert T. Manguso, Hans W. Pope et al. Nature profile →
  2. PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity
    2017 612 citations Vikram R. Juneja, Kathleen A. McGuire et al. The Journal of Experimental Medicine profile →

Peers

Vikram R. Juneja
Cristina Maccalli Italy
Todd D. Armstrong United States
Jasreet Hundal United States
Klara Balint United States
Serena S. Kwek United States
Michael P. Rettig United States
Katelyn T. Byrne United States
Tomohide Tsukahara Japan
Malin Pedersen United Kingdom
Stephen Mok United States
Cristina Maccalli Italy
Vikram R. Juneja
Citations per year, relative to Vikram R. Juneja Vikram R. Juneja (= 1×) peers Cristina Maccalli

Countries citing papers authored by Vikram R. Juneja

Since Specialization
Citations

This map shows the geographic impact of Vikram R. Juneja's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vikram R. Juneja with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vikram R. Juneja more than expected).

Fields of papers citing papers by Vikram R. Juneja

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vikram R. Juneja. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vikram R. Juneja. The network helps show where Vikram R. Juneja may publish in the future.

Co-authorship network of co-authors of Vikram R. Juneja

This figure shows the co-authorship network connecting the top 25 collaborators of Vikram R. Juneja. A scholar is included among the top collaborators of Vikram R. Juneja based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vikram R. Juneja. Vikram R. Juneja is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Yee, Christina, et al.. (2025). Generation of T cell responses against broad KRAS hotspot neoantigens for cell therapy or TCR discovery. Cell Reports Methods. 5(5). 101049–101049. 1 indexed citations
2.
Pauken, Kristen E., Vikram R. Juneja, Kelly P. Burke, et al.. (2025). PD-1 regulates tumor-infiltrating CD8+ T cells in both a cell-intrinsic and a cell-extrinsic fashion. The Journal of Experimental Medicine. 222(10). 1 indexed citations
3.
Bu, Xia, Vikram R. Juneja, Carol Reynolds, et al.. (2021). Monitoring PD-1 Phosphorylation to Evaluate PD-1 Signaling during Antitumor Immune Responses. Cancer Immunology Research. 9(12). 1465–1475. 11 indexed citations
4.
Goulding, Scott P., Daniel Rothenberg, John Srouji, et al.. (2021). Systematic discovery and validation of T cell targets directed against oncogenic KRAS mutations. Cell Reports Methods. 1(5). 100084–100084. 34 indexed citations
5.
Drijvers, Jefte M., Jacob E. Gillis, Thao H. Nguyen, et al.. (2020). Pharmacologic Screening Identifies Metabolic Vulnerabilities of CD8+ T Cells. Cancer Immunology Research. 9(2). 184–199. 137 indexed citations
6.
Chen, Ivy X., Kristen E. Pauken, Vikram R. Juneja, et al.. (2020). A bilateral tumor model identifies transcriptional programs associated with patient response to immune checkpoint blockade. Proceedings of the National Academy of Sciences. 117(38). 23684–23694. 32 indexed citations
7.
Kuchroo, Juhi R., Peter T. Sage, Dan Liang, et al.. (2020). PD-1 restraint of regulatory T cell suppressive activity is critical for immune tolerance. The Journal of Experimental Medicine. 218(1). 181 indexed citations
8.
Mooradian, Meghan J., Alexandre Reuben, Peter A. Prieto, et al.. (2018). A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma. OncoImmunology. 7(5). e1423172–e1423172. 20 indexed citations
9.
Manguso, Robert T., Hans W. Pope, Margaret D. Zimmer, et al.. (2017). In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. Nature. 547(7664). 413–418. 774 indexed citations breakdown →
10.
Pauken, Kristen E., Vikram R. Juneja, Kathleen L. McGuire, et al.. (2017). CD8+ T cell-independent mechanisms of PD-1-mediated suppression of anti-tumor immunity in mice. The Journal of Immunology. 198(Supplement_1). 205.11–205.11. 2 indexed citations
11.
Kaul, V. K., et al.. (2017). Mauriac Syndrome: Rare Complication in Type-1 Diabetic Children. Pediatrics & Therapeutics. 7(4). 1 indexed citations
12.
Juneja, Vikram R., Kathleen A. McGuire, Robert T. Manguso, et al.. (2017). PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity. The Journal of Experimental Medicine. 214(4). 895–904. 612 indexed citations breakdown →
13.
Sage, Peter T., Noga Ron‐Harel, Vikram R. Juneja, et al.. (2016). Suppression by TFR cells leads to durable and selective inhibition of B cell effector function. Nature Immunology. 17(12). 1436–1446. 176 indexed citations
14.
Paterson, Alison M., Scott B. Lovitch, Peter T. Sage, et al.. (2015). Deletion of CTLA-4 on regulatory T cells during adulthood leads to resistance to autoimmunity. The Journal of Experimental Medicine. 212(10). 1603–1621. 172 indexed citations
15.
Cooper, Zachary A., Vikram R. Juneja, Peter T. Sage, et al.. (2014). Response to BRAF Inhibition in Melanoma Is Enhanced When Combined with Immune Checkpoint Blockade. Cancer Immunology Research. 2(7). 643–654. 192 indexed citations
16.
Cooper, Zachary A., Dennie T. Frederick, Vikram R. Juneja, et al.. (2013). BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytes. OncoImmunology. 2(10). e26615–e26615. 84 indexed citations
17.
Xu, Chenjie, David Miranda-Nieves, James A. Ankrum, et al.. (2012). Tracking Mesenchymal Stem Cells with Iron Oxide Nanoparticle Loaded Poly(lactide-co-glycolide) Microparticles. Nano Letters. 12(8). 4131–4139. 119 indexed citations
18.
Driskell, Ryan R., Vikram R. Juneja, John T. Connelly, et al.. (2011). Clonal Growth of Dermal Papilla Cells in Hydrogels Reveals Intrinsic Differences between Sox2-Positive and -Negative Cells In Vitro and In Vivo. Journal of Investigative Dermatology. 132(4). 1084–1093. 61 indexed citations
19.
Altuna, Xabier, Jay Patrick Lopez, Yi An, et al.. (2009). p73 Expression and Function in Vestibular Schwannoma. Archives of Otolaryngology - Head and Neck Surgery. 135(7). 662–662. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Cristina Maccalli Breakdown of academic impact, for papers by Todd D. Armstrong Breakdown of academic impact, for papers by Jasreet Hundal Breakdown of academic impact, for papers by Klara Balint Breakdown of academic impact, for papers by Serena S. Kwek Breakdown of academic impact, for papers by Michael P. Rettig Breakdown of academic impact, for papers by Katelyn T. Byrne Breakdown of academic impact, for papers by Tomohide Tsukahara Breakdown of academic impact, for papers by Malin Pedersen Breakdown of academic impact, for papers by Stephen Mok
Rankless by CCL
2026